Our products and methods are patented in all key markets, including Australia, China, India, Japan, South Korea, Hong Kong SAR, Macau SAR, European Union (Germany, France, United Kingdom, Italy, Spain, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, Austria, Norway, Denmark, Ireland and Finland), Canada, South Africa, New Zealand, Singapore, Malaysia, Vietnam, Indonesia, USA and Israel.

The patents cover fast-dissolving oral dosage forms and methods for the release of biologically active materials in the oral cavity. Additionally, the particular dosage form may contain and deliver a wide range of biologically active materials and is not limited to a specific biologically active material. Methods for use and for the production of the fast dissolving oral dosage forms are also provided.

Our patents strategy uses the Patent Cooperation Treaty system to obtain broad protection for our product portfolio in participating countries, which covers the WaferiX® technology, our products as well as potential new formulations and methods of use. We aim to secure patent protection for our products and methods in all relevant jurisdictions, as and when necessary. In most countries, the term awarded for a granted patent is 20 years from the date of application.

Contact us

iX Biopharma Ltd

1 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170